Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...

Merck & Co. Inc. closed 27.25% short of its 52-week high of $134.63, which the company reached on June 25th.

Merck (MRK) announced that the board of directors has declared a quarterly dividend of 81c per share of the company’s common stock for the ...

In the most recent trading session, Merck (MRK) closed at $97.45, indicating a -0.5% shift from the previous trading day.

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $97.94 which represents a slight increase of $2.39 or 2.50% from the prior close of $95.55. The stock opened at $96.63 and touched a ...

Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...

Citi lowered the firm’s price target on Merck (MRK) to $125 from $130 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the firm ...

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.

Summer camp registration at Merck Forest & Farmland Center officially opens on February 7 at 9 a.m. With programs designed ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...